For example, patients taking tirzepatide have seen average weight reductions of up to 22.5% of their body weight, while those on semaglutide (at the weight management dose) have averaged around 15% weight loss
Univariate analysis provides a straightforward assessment of individual features, highlighting those with significant differences between groups
Aghsaeifard Z, et al
Compounded semaglutide mimics this hormone by: Enhancing insulin secretion and reducing glucagon release
Heterogeneous findings are organized by intervention/comparator, follow-up window, and key effect modifiers, including baseline obesity/insulin-resistance phenotype, concomitant metformin, and lifestyle co-interventions
Within two years, the vast majority of patients have stopped taking their GLP-1 agonists